The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access
Discussions focused on digital health, non-communicable diseases, resilient supply chains, medical innovation, and healthcare workforce development
Keeps Halo Pharma to drive independent growth
Enterprise-scale adoption in 2026 will be driven by domain-specific AI, compliance automation, and strong digital foundations across quality, manufacturing and regulatory workflows
The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Funds to support product expansion, quick commerce growth, and manufacturing scale-up for holistic period care solutions
Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
Subscribe To Our Newsletter & Stay Updated
